NCT03541174: A trial that was reported late by Idorsia Pharmaceuticals Ltd.
This trial has reported, although it was 178 days late in doing so.
Full data
Full entry on ClinicalTrials.gov | NCT03541174 |
---|---|
Title | Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT) |
Results Status | Reported (late) |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | June 18, 2018 |
Completion date | May 14, 2021 |
Required reporting date | May 14, 2022, midnight |
Actual reporting date | Nov. 8, 2022 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | 178 |